Research map: Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction‐Associated Steatohepatitis—Reanalysis of Fibrosis Stage 2–3 Subset

Back to the article

Papers in this map

  1. Design and validation of a histological scoring system for nonalcoholic fatty liver disease† · David Erwin Kleiner · 2005 · 10909 citations · Cited by this paper
  2. International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update · Maria Mironova · 2026 · Cites this paper
  3. Review Article: Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine · 2026 · Related
  4. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases · Naga Chalasani · 2017 · 7417 citations · Cited by this paper
  5. Letter: External Validation of Hepcidin Thresholds for Predicting Response to Iron Therapy in Active Inflammatory Bowel Disease · 2026 · Related
  6. Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes Federation · K. G. M. M. Alberti · 2006 · 6653 citations · Cited by this paper
  7. Development and Validation of a Machine Learning Model to Prognosticate Hepatocellular Carcinoma · 2026 · Related
  8. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review · Zobair M. Younossi · 2023 · 3310 citations · Cited by this paper
  9. Natural History of Recurrent Acute Pancreatitis: Implications for Interventional Trial Design · 2026 · Related
  10. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease · Mary Eugenia Rinella · 2023 · 2555 citations · Cited by this paper
  11. Letter: Low FODMAP Therapy in Paediatric Irritable Bowel Syndrome: Balancing Efficacy, Expectancy and Safety · 2026 · Related
  12. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease · Chris Estes · 2017 · 2456 citations · Cited by this paper
  13. Letter: Does the Association Between Mild Endoscopic Activity and Adverse Outcomes Justify Treatment Escalation in Older Adults With Inflammatory Bowel Disease? · 2026 · Related
  14. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis · Stephen A. Harrison · 2024 · 1982 citations · Cited by this paper
  15. Eosinophilic Oesophagitis Beyond the Oesophagus: High Prevalence of Chronic Rhinosinusitis‐Type Symptoms and Their Impact on Symptom Severity in Swiss EoE Cohort Study Patients · 2026 · Related
  16. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis · Parambir Singh Dulai · 2017 · 1972 citations · Cited by this paper
  17. Non‐Selective Beta‐Blocker Use Is Associated With Lower Mortality After Decompensation in Cirrhosis: A Nationwide Target Trial Emulation · 2026 · Related
  18. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe · Zobair M. Younossi · 2016 · 1317 citations · Cited by this paper
  19. Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study · 2026 · Related
  20. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease · Arun Jayant Sanyal · 2021 · 1134 citations · Cited by this paper
  21. A Distinct Immune Signature Characterizes Cirrhosis in Ethiopian Individuals With Chronic HBV Infection · 2026 · Related
  22. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial · Stephen A. Harrison · 2019 · 798 citations · Cited by this paper
  23. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial · Stephen A. Harrison · 2023 · 429 citations · Cited by this paper
  24. Metabolic dysfunction-associated steatotic liver disease in adults · Daniel Q. Huang · 2025 · 286 citations · Cited by this paper
  25. Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis in five European countries in 2018: A cost‐of‐illness analysis · Jörn Markus Schattenberg · 2021 · 146 citations · Cited by this paper
  26. Increased Hepatic Fat Content in Patients with Resistance to Thyroid Hormone Beta · Carolina Marques Chaves · 2020 · 61 citations · Cited by this paper
  27. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy · Jiannis Anastasiou · 2010 · 41 citations · Cited by this paper
  28. Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis · Wenhao Li · 2025 · 30 citations · Cited by this paper

Source: OpenAlex (CC0)